Antengene Corporation Limited, a leading commercial-stage global biopharmaceutical company, announced that it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the phase I trial of ATG-018 in patients with advanced solid tumours and hematologic malignancies (ATRIUM Trial).
ATG-018 is an orally-available, potent, selective small molecule ATR inhibitor. ATG-018 inhibits the ATR kinase, thus limiting cancer cells
